Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer

Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region

NCT03082976 ·Status: COMPLETED

Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom

NCT00757263 ·Status: UNKNOWN

Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA

NCT03229122 ·Status: COMPLETED

Search for Predictors of Therapeutic Response in Ovarian Carcinoma

NCT01391351 ·Status: COMPLETED ·Phase: NA

BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary

NCT06304922 ·Status: NOT_YET_RECRUITING

Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer

NCT04752865 ·Status: UNKNOWN

Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer

NCT03656809 ·Status: COMPLETED

Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.

NCT02341118 ·Status: TERMINATED

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

NCT02900560 ·Status: TERMINATED ·Phase: PHASE2

Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00288275 ·Status: TERMINATED

Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India

NCT03471572 ·Status: COMPLETED

Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation

NCT05763472 ·Status: UNKNOWN

Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients

NCT04152941 ·Status: COMPLETED

China Ovarian Cancer BRCA Testing Study

NCT03203993 ·Status: TERMINATED

Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma

NCT03302884 ·Status: UNKNOWN ·Phase: NA

FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study

NCT02984423 ·Status: COMPLETED

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

NCT00466986 ·Status: COMPLETED ·Phase: PHASE2

Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study

NCT04091204 ·Status: UNKNOWN ·Phase: PHASE2

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

NCT03943173 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1

Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function

NCT00525460 ·Status: COMPLETED

Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response

NCT03831230 ·Status: COMPLETED

NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma

NCT06972693 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer

NCT00039559 ·Status: UNKNOWN ·Phase: NA

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02316834 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors

NCT04675320 ·Status: UNKNOWN